Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2023-03-09 00:00:00 ET · period of report 2023-03-07 · accession 0001209191-23-017636 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-03-09 | 2023-03-07 | XENE | PIMSTONE SIMON N. | Dir | F - Tax | $37.13 | -3,778 | 63.2K | -6% | -$140.3K |
| DM | 2023-03-09 | 2023-03-07 | XENE | PIMSTONE SIMON N. | Dir | S - Sale+OE | $36.98 | -19.2K | 34.0K | -36% | -$711.2K |
| DM | 2023-03-09 | 2023-03-07 | XENE | PIMSTONE SIMON N. | Dir | M - OptEx | $2.64 | +72.0K | 47.2K | New | +$190.2K |
| DM | 2023-03-09 | 2023-03-07 | XENE | PIMSTONE SIMON N. | Dir | M - OptEx | $0.00 | -72.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-03-07 | F | D | 2,160 | $37.13 | 44,992 | D | — | — | (F2) Represents the closing price of the Company's common shares on March 6, 2023 for purposes of net settlement calculations. |
| 2 | Common | Common Shares | 2023-03-07 | S | D | 8,242 | $36.94 | 55,006 | D | — | — | (F4) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.89 to $37.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 3 | Common | Common Shares | 2023-03-07 | F | D | 1,618 | $37.13 | 63,248 | D | — | — | (F2) Represents the closing price of the Company's common shares on March 6, 2023 for purposes of net settlement calculations. |
| 4 | Common | Common Shares | 2023-03-07 | M | A | 30,864 | $2.59 | 64,866 | D | — | — | (F1) The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. |
| 5 | Common | Common Shares | 2023-03-07 | S | D | 10,990 | $37.01 | 34,002 | D | — | — | (F3) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.93 to $37.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 6 | Common | Common Shares | 2023-03-07 | M | A | 41,152 | $2.68 | 47,152 | D | — | — | (F1) The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. |
| 7 | Derivative | Stock Option (Right to Buy) | 2023-03-07 | M | D | 30,864 | $0.00 | 0 | D | $2.59 · — to 2023-03-09 | 30,864 Common Shares | (F1) The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. (F5) The shares subject to the options are fully vested and exercisable. |
| 8 | Derivative | Stock Option (Right to Buy) | 2023-03-07 | M | D | 41,152 | $0.00 | 0 | D | $2.68 · — to 2023-03-10 | 41,152 Common Shares | (F1) The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. (F5) The shares subject to the options are fully vested and exercisable. (F6) Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. |